$51.08
Insights on Procept Biorobotics
Revenue is up for the last 15 quarters, 1.19M → 43.58M (in $), with an average increase of 21.1% per quarter
Netprofit is down for the last 2 quarters, -24.62M → -27.50M (in $), with an average decrease of 11.7% per quarter
0.2%
Downside
Day's Volatility :5.47%
Upside
5.28%
51.39%
Downside
52 Weeks Volatility :54.44%
Upside
6.28%
Period | Procept Biorobotics | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.81% | -0.7% | 0.0% |
6 Months | 83.85% | 6.6% | 0.0% |
1 Year | 39.9% | 3.7% | -1.5% |
3 Years | 23.49% | 14.0% | -21.8% |
Market Capitalization | 2.6B |
Book Value | $5.53 |
Earnings Per Share (EPS) | -2.24 |
Wall Street Target Price | 58.57 |
Profit Margin | -77.76% |
Operating Margin TTM | -67.82% |
Return On Assets TTM | -19.11% |
Return On Equity TTM | -44.33% |
Revenue TTM | 136.2M |
Revenue Per Share TTM | 2.88 |
Quarterly Revenue Growth YOY | 83.3% |
Gross Profit TTM | 37.1M |
EBITDA | -105.4M |
Diluted Eps TTM | -2.24 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.0 |
EPS Estimate Next Year | -1.52 |
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Next Quarter | -0.52 |
What analysts predicted
Upside of 14.66%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 6.2M | - |
Net Income | -42.7M | - |
Net Profit Margin | -691.41% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.7M | ↑ 25.09% |
Net Income | -58.3M | ↑ 36.58% |
Net Profit Margin | -754.89% | ↓ 63.48% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 34.5M | ↑ 346.72% |
Net Income | -62.4M | ↑ 7.09% |
Net Profit Margin | -180.96% | ↑ 573.93% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 75.0M | ↑ 117.6% |
Net Income | -93.6M | ↑ 50.01% |
Net Profit Margin | -124.76% | ↑ 56.2% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 136.2M | ↑ 81.55% |
Net Income | -105.9M | ↑ 13.16% |
Net Profit Margin | -77.76% | ↑ 47.0% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 20.3M | ↑ 21.92% |
Net Income | -23.1M | ↑ 12.82% |
Net Profit Margin | -113.62% | ↑ 9.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 23.8M | ↑ 16.85% |
Net Income | -31.3M | ↑ 35.39% |
Net Profit Margin | -131.66% | ↓ 18.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.4M | ↑ 2.64% |
Net Income | -27.7M | ↓ 11.5% |
Net Profit Margin | -113.53% | ↑ 18.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.1M | ↑ 35.65% |
Net Income | -25.3M | ↓ 8.73% |
Net Profit Margin | -76.38% | ↑ 37.15% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 35.1M | ↑ 6.04% |
Net Income | -24.6M | ↓ 2.62% |
Net Profit Margin | -70.14% | ↑ 6.24% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 43.6M | ↑ 24.16% |
Net Income | -27.5M | ↑ 11.7% |
Net Profit Margin | -63.11% | ↑ 7.03% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 62.0M | - |
Total Liabilities | 205.8M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 126.0M | ↑ 103.2% |
Total Liabilities | 308.9M | ↑ 50.06% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 337.0M | ↑ 167.54% |
Total Liabilities | 69.9M | ↓ 77.36% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 309.3M | ↓ 8.22% |
Total Liabilities | 112.3M | ↑ 60.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 404.7M | ↑ 30.84% |
Total Liabilities | 124.0M | ↑ 10.43% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 324.0M | ↑ 4.22% |
Total Liabilities | 103.3M | ↑ 43.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 309.3M | ↓ 4.54% |
Total Liabilities | 112.3M | ↑ 8.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 284.5M | ↓ 8.04% |
Total Liabilities | 111.3M | ↓ 0.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 272.4M | ↓ 4.22% |
Total Liabilities | 116.5M | ↑ 4.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 421.1M | ↑ 54.57% |
Total Liabilities | 121.8M | ↑ 4.48% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 404.7M | ↓ 3.9% |
Total Liabilities | 124.0M | ↑ 1.8% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -43.8M | - |
Investing Cash Flow | 43.2M | - |
Financing Cash Flow | 26.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -48.3M | ↑ 10.33% |
Investing Cash Flow | -233.0K | ↓ 100.54% |
Financing Cash Flow | 106.8M | ↑ 302.5% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -57.3M | ↑ 18.6% |
Investing Cash Flow | -592.0K | ↑ 154.08% |
Financing Cash Flow | 262.1M | ↑ 145.49% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -80.4M | ↑ 40.2% |
Investing Cash Flow | -2.7M | ↑ 348.14% |
Financing Cash Flow | 3.6M | ↓ 98.62% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.9M | ↑ 15.91% |
Investing Cash Flow | -1.5M | ↑ 594.5% |
Financing Cash Flow | 777.0K | ↓ 72.85% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↑ 26.81% |
Investing Cash Flow | -866.0K | ↓ 42.8% |
Financing Cash Flow | -1.3M | ↓ 269.63% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -35.9M | ↑ 42.72% |
Investing Cash Flow | -5.3M | ↑ 516.51% |
Financing Cash Flow | 380.0K | ↓ 128.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -28.3M | ↓ 21.12% |
Investing Cash Flow | -5.4M | ↑ 0.62% |
Financing Cash Flow | 2.4M | ↑ 539.47% |
Sell
Neutral
Buy
Procept Biorobotics is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Procept Biorobotics | 6.34% | 83.85% | 39.9% | 23.49% | 23.49% |
Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Procept Biorobotics | 53.06 | NA | NA | -2.0 | -0.44 | -0.19 | NA | 5.53 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Procept Biorobotics | Buy | $2.6B | 23.49% | 53.06 | -77.76% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
FMR Inc
Cpmg Inc
Vanguard Group Inc
T. Rowe Price Investment Management,Inc.
BlackRock Inc
AllianceBernstein L.P.
based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.
Organization | Procept Biorobotics |
Employees | 626 |
CEO | Dr. Reza Zadno Ph.D. |
Industry | Healthcare |
Patterson Companies, Inc.
$51.08
-1.37%
Springworks Therapeutics Inc
$51.08
-1.37%
Penumbra Inc
$51.08
-1.37%
Corcept Therapeutics Inc
$51.08
-1.37%
Tenet Healthcare Corp.
$51.08
-1.37%
Integer Holdings Corp
$51.08
-1.37%
Chemed Corp.
$51.08
-1.37%
Amn Healthcare Services Inc.
$51.08
-1.37%
Acadia Pharmaceuticals Inc.
$51.08
-1.37%